Cargando…
Resistance on the Latest Oral and Intravenous P2Y12 ADP Receptor Blockers in Patients with Acute Coronary Syndromes: Fact or Myth?
Novel P2Y12 ADP receptor blockers (ADPRB) should be preferred in dual-antiplatelet therapy in patients with acute coronary syndrome. Nevertheless, there are still patients who do not respond optimally to novel ADP receptor blocker therapy, and this nonoptimal response (so-called “high on-treatment p...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9737839/ https://www.ncbi.nlm.nih.gov/pubmed/36498785 http://dx.doi.org/10.3390/jcm11237211 |
_version_ | 1784847388138012672 |
---|---|
author | Blaško, Peter Samoš, Matej Bolek, Tomáš Stančiaková, Lucia Škorňová, Ingrid Péč, Martin Jozef Jurica, Jakub Staško, Ján Mokáň, Marián |
author_facet | Blaško, Peter Samoš, Matej Bolek, Tomáš Stančiaková, Lucia Škorňová, Ingrid Péč, Martin Jozef Jurica, Jakub Staško, Ján Mokáň, Marián |
author_sort | Blaško, Peter |
collection | PubMed |
description | Novel P2Y12 ADP receptor blockers (ADPRB) should be preferred in dual-antiplatelet therapy in patients with acute coronary syndrome. Nevertheless, there are still patients who do not respond optimally to novel ADP receptor blocker therapy, and this nonoptimal response (so-called “high on-treatment platelet reactivity” or “resistance”) could be connected with increased risk of adverse ischemic events, such as myocardial re-infarction, target lesion failure and stent thrombosis. In addition, several risk factors have been proposed as factors associated with the phenomenon of inadequate response on novel ADPRB. These include obesity, multivessel coronary artery disease, high pre-treatment platelet reactivity and impaired metabolic status for prasugrel, as well as elderly, concomitant therapy with beta-blockers, morphine and platelet count for ticagrelor. There is no literature report describing nonoptimal therapeutic response on cangrelor, and cangrelor therapy seems to be a possible approach for overcoming HTPR on prasugrel and ticagrelor. However, the optimal therapeutic management of “resistance” on novel ADPRB is not clear and this issue requires further research. This narrative review article discusses the phenomenon of high on-treatment platelet reactivity on novel ADPRB, its importance in clinical practice and approaches for its therapeutic overcoming. |
format | Online Article Text |
id | pubmed-9737839 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-97378392022-12-11 Resistance on the Latest Oral and Intravenous P2Y12 ADP Receptor Blockers in Patients with Acute Coronary Syndromes: Fact or Myth? Blaško, Peter Samoš, Matej Bolek, Tomáš Stančiaková, Lucia Škorňová, Ingrid Péč, Martin Jozef Jurica, Jakub Staško, Ján Mokáň, Marián J Clin Med Review Novel P2Y12 ADP receptor blockers (ADPRB) should be preferred in dual-antiplatelet therapy in patients with acute coronary syndrome. Nevertheless, there are still patients who do not respond optimally to novel ADP receptor blocker therapy, and this nonoptimal response (so-called “high on-treatment platelet reactivity” or “resistance”) could be connected with increased risk of adverse ischemic events, such as myocardial re-infarction, target lesion failure and stent thrombosis. In addition, several risk factors have been proposed as factors associated with the phenomenon of inadequate response on novel ADPRB. These include obesity, multivessel coronary artery disease, high pre-treatment platelet reactivity and impaired metabolic status for prasugrel, as well as elderly, concomitant therapy with beta-blockers, morphine and platelet count for ticagrelor. There is no literature report describing nonoptimal therapeutic response on cangrelor, and cangrelor therapy seems to be a possible approach for overcoming HTPR on prasugrel and ticagrelor. However, the optimal therapeutic management of “resistance” on novel ADPRB is not clear and this issue requires further research. This narrative review article discusses the phenomenon of high on-treatment platelet reactivity on novel ADPRB, its importance in clinical practice and approaches for its therapeutic overcoming. MDPI 2022-12-04 /pmc/articles/PMC9737839/ /pubmed/36498785 http://dx.doi.org/10.3390/jcm11237211 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Blaško, Peter Samoš, Matej Bolek, Tomáš Stančiaková, Lucia Škorňová, Ingrid Péč, Martin Jozef Jurica, Jakub Staško, Ján Mokáň, Marián Resistance on the Latest Oral and Intravenous P2Y12 ADP Receptor Blockers in Patients with Acute Coronary Syndromes: Fact or Myth? |
title | Resistance on the Latest Oral and Intravenous P2Y12 ADP Receptor Blockers in Patients with Acute Coronary Syndromes: Fact or Myth? |
title_full | Resistance on the Latest Oral and Intravenous P2Y12 ADP Receptor Blockers in Patients with Acute Coronary Syndromes: Fact or Myth? |
title_fullStr | Resistance on the Latest Oral and Intravenous P2Y12 ADP Receptor Blockers in Patients with Acute Coronary Syndromes: Fact or Myth? |
title_full_unstemmed | Resistance on the Latest Oral and Intravenous P2Y12 ADP Receptor Blockers in Patients with Acute Coronary Syndromes: Fact or Myth? |
title_short | Resistance on the Latest Oral and Intravenous P2Y12 ADP Receptor Blockers in Patients with Acute Coronary Syndromes: Fact or Myth? |
title_sort | resistance on the latest oral and intravenous p2y12 adp receptor blockers in patients with acute coronary syndromes: fact or myth? |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9737839/ https://www.ncbi.nlm.nih.gov/pubmed/36498785 http://dx.doi.org/10.3390/jcm11237211 |
work_keys_str_mv | AT blaskopeter resistanceonthelatestoralandintravenousp2y12adpreceptorblockersinpatientswithacutecoronarysyndromesfactormyth AT samosmatej resistanceonthelatestoralandintravenousp2y12adpreceptorblockersinpatientswithacutecoronarysyndromesfactormyth AT bolektomas resistanceonthelatestoralandintravenousp2y12adpreceptorblockersinpatientswithacutecoronarysyndromesfactormyth AT stanciakovalucia resistanceonthelatestoralandintravenousp2y12adpreceptorblockersinpatientswithacutecoronarysyndromesfactormyth AT skornovaingrid resistanceonthelatestoralandintravenousp2y12adpreceptorblockersinpatientswithacutecoronarysyndromesfactormyth AT pecmartinjozef resistanceonthelatestoralandintravenousp2y12adpreceptorblockersinpatientswithacutecoronarysyndromesfactormyth AT juricajakub resistanceonthelatestoralandintravenousp2y12adpreceptorblockersinpatientswithacutecoronarysyndromesfactormyth AT staskojan resistanceonthelatestoralandintravenousp2y12adpreceptorblockersinpatientswithacutecoronarysyndromesfactormyth AT mokanmarian resistanceonthelatestoralandintravenousp2y12adpreceptorblockersinpatientswithacutecoronarysyndromesfactormyth |